Information  X 
Enter a valid email address

MaxCyte, Inc. (MXCT)

  Print      Mail a friend

Tuesday 05 March, 2019

MaxCyte, Inc.

Grant of Options

RNS Number : 8081R
MaxCyte, Inc.
05 March 2019
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options

 

Maryland, USA - 05 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that on 04 March 2019, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

 

Option Grants to PDMRs


Doerfler, Doug

390,200

Holtz, Ron

177,600

Thompson, J. Stark

26,900

Mandell, Art

26,900

Erck, Stan

26,900

Brooke, Will

26,900

Johnston, John

26,900

Douglas, Richard

26,900

Total

729,200

 

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 04 March 2019, of 177.50 pence.

 

 

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

 

 1

Details of the person discharging managerial responsibilities / person closely associated 

a)

Names 

Doerfler, Doug

Holtz, Ron

Thompson, J. Stark

Mandell, Art

Erck, Stan

Brooke, Will

Johnston, John

Douglas, Richard

2

Reason for the notification

a)

Position/status

 

Doerfler, Doug - CEO and Director

Holtz, Ron - CFO and Director

Thompson, J. Stark - Non-executive Chairman

Mandell, Art - Non-executive Director

Erck, Stan - Non-executive Director

Brooke, Will - Non-executive Director

Johnston, John - Non-executive Director

Douglas, Richard - Non-executive Director

b)

Initial notification /Amendment 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Grant of Options over Shares of Common Stock

b)

Identification code  

US57777K1060

c)

Nature of the transactions  

 

Grant of Options to PDMRs

d)

 

Price(s) and volume(s)

Doerfler, Doug - 390,200 at an exercise price of 177.50  pence

Holtz, Ron - 177,600 at an exercise price of 177.50  pence

Thompson, J. Stark - 26,900 at an exercise price of 177.50  pence

Mandell, Art - 26,900 at an exercise price of 177.50  pence

Erck, Stan - 26,900 at an exercise price of 177.50  pence

Brooke, Will - 26,900 at an exercise price of 177.50  pence

Johnston, John - 26,900 at an exercise price of 177.50  pence

Douglas, Richard - 26,900 at an exercise price of 177.50  pence

d)

 

Aggregated information 

- Aggregated volume

- Price

 n/a 

e)

 

Date of the transactions 

04 March 2019

f) 

Place of the transaction

Outside a trading venue

 

 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 

 

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer




Nominated Adviser and Broker

Panmure Gordon (UK) Limited

Emma Earl  (Corporate Finance)

Freddy Crossley

James Stearns (Corporate Broking)

 

+44 (0) 20 7886 2500

 

Financial PR Adviser

Consilium Strategic Communications

+44 (0)20 3709 5700

[email protected]

Mary-Jane Elliott


 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEANDLEDPNEFF

a d v e r t i s e m e n t